I thank the authors for their kind and thoughtful comments regarding our recently published article.1 My colleagues and I applaud their recent publication2 and others3,4 that have illustrated remarkable results with the use of beta-blockers for infantile hemangioma with limited deleterious sequelae. In contrast, there are reports of adverse events that cannot be ignored,5–7 because unrecognized hypoglycemia, bronchospasm, hypotension, or bradycardia could produce a disastrous outcome. Furthermore, to date, propranolol has not been shown to be a panacea, and for a complicated hemangioma producing functional problems, aggressive intervention may be requisite.8
Advances in a particular field of medicine ideally occur in a translational research model in which hypothesis-driven bench research can then be studied in well-structured human trials. However, on occasion, medical advances are serendipitous in nature and controlled study occurs in reverse fashion, which is, of course, the status of beta-blockers for the treatment of infantile hemangioma. Our goal as consultants is to provide best practices of patient care through careful scrutiny of evidence surrounding new innovation; a departure from this tenet could lead to breach of the dictum primum non nocere. It is well acknowledged that advances are initially met with an excitement period, followed by an evaluative and reflective period, with the ultimate arrival at a steady state of accepted clinical utility. It can be argued that the “jury is still deliberating” on the true place of beta-blockers in the treatment algorithm for infantile hemangioma because of absence of a published controlled prospective trial; in time, the collective body of literature on this subject will define treatment indications, therapeutic regimen, clinical efficacy, complication profile, and mechanism of action.
Finally, I would be remiss if I did not congratulate their institution's vascular birthmark center, because through research, teaching, and multidisciplinary clinical care of patients with vascular anomalies, a future generation of “next practices” will surely be cultivated.
Jugpal S. Arneja, M.D.
University of British Columbia
British Columbia Children's Hospital
Division of Plastic Surgery
A237 Shaughnessy Building, Box 150
4480 Oak Street
Vancouver, British Columbia V6H 3V4, Canada
1. Arneja JS, Pappas PN, Shwayder TA, et al. Management of complicated facial hemangiomas with beta-blocker (propranolol) therapy. Plast Reconstr Surg
2. Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg.
Epublished ahead of print August 4, 2010.
3. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med
4. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: Follow-up report. Pediatrics
5. Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol
6. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: Risks and recommendations. Pediatr Dermatol
7. Breur JM, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: A case report. Pediatr Dermatol.
Epublished ahead of print August 4, 2010.
8. Arneja JS, Mulliken JB. Resection of amblyogenic periocular hemangiomas: Indications and outcomes. Plast Reconstr Surg
Letters to the Editor, discussing material recently published in the Journal, are welcome. They will have the best chance of acceptance if they are received within 8 weeks of an article's publication. Letters to the Editor may be published with a response from the authors of the article being discussed. Discussions beyond the initial letter and response will not be published. Letters submitted pertaining to published Discussions of articles will not be printed. Letters to the Editor are not usually peer reviewed, but the Journal may invite replies from the authors of the original publication. All Letters are published at the discretion of the Editor.
Authors will be listed in the order in which they appear in the submission. Letters should be submitted electronically via PRS' enkwell, at www.editorialmanager.com/prs/.
We reserve the right to edit Letters to meet requirements of space and format. Any financial interests relevant to the content of the correspondence must be disclosed. Submission of a Letter constitutes permission for the American Society of Plastic Surgeons and its licensees and asignees to publish it in the Journal and in any other form or medium.
The views, opinions, and conclusions expressed in the Letters to the Editor represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.